Cargando…

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)

OBJECTIVE: Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn’s disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported. DESIGN: Parallel-group, dose-ranging, double-blind trial with 4-week screening and 12-week treatment periods. After...

Descripción completa

Detalles Bibliográficos
Autores principales:	Danese, Silvio, Vermeire, Séverine, Hellstern, Paul, Panaccione, Remo, Rogler, Gerhard, Fraser, Gerald, Kohn, Anna, Desreumaux, Pierre, Leong, Rupert W, Comer, Gail M, Cataldi, Fabio, Banerjee, Anindita, Maguire, Mary K, Li, Cheryl, Rath, Natalie, Beebe, Jean, Schreiber, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839832/ https://www.ncbi.nlm.nih.gov/pubmed/29247068 http://dx.doi.org/10.1136/gutjnl-2017-314562

Ejemplares similares

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial
por: Panés, Julian, et al.
Publicado: (2023)

A microbial signature for Crohn's disease
por: Pascal, Victoria, et al.
Publicado: (2017)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study
por: Ma, Christopher, et al.
Publicado: (2017)

Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
por: Hart, Ailsa, et al.
Publicado: (2022)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
por: Sandborn, William J, et al.
Publicado: (2018)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2023)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?—A prospective study
por: Magro, Fernando, et al.
Publicado: (2023)

Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
por: Bouhnik, Yoram, et al.
Publicado: (2018)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
por: Verstockt, Bram, et al.
Publicado: (2023)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn’s disease recurrence
por: Khaloian, Sevana, et al.
Publicado: (2020)

A novel unconventional T cell population enriched in Crohn’s disease
por: Rosati, Elisa, et al.
Publicado: (2022)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
por: Cornillie, Freddy, et al.
Publicado: (2014)

Bacterial protein signals are associated with Crohn’s disease
por: Juste, Catherine, et al.
Publicado: (2014)

Treat‐to‐target and sequencing therapies in Crohn's disease
por: Garcia, Nicole M., et al.
Publicado: (2022)

Diversion proctocolitis and the problem of the forgotten rectum in inflammatory bowel diseases: A systematic review
por: Dal Buono, Arianna, et al.
Publicado: (2021)

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease
por: Schmitt, Heike, et al.
Publicado: (2019)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Inability to walk: a rare presentation of Crohn’s disease
por: Hoekstra, Elmer, et al.
Publicado: (2020)

Variables associated with progression of moderate-to-severe Crohn’s disease
por: Sacramento, Carolina da Silva Beda, et al.
Publicado: (2022)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Factors affecting outcomes in Crohn's disease over 15 years
por: Cosnes, Jacques, et al.
Publicado: (2012)

Creeping fat formation and interaction with intestinal disease in Crohn's disease
por: Yin, Yi, et al.
Publicado: (2022)

Real‐world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey
por: Nardone, Olga Maria, et al.
Publicado: (2023)

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
por: Colombel, Jean-Frederic, et al.
Publicado: (2014)

Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale
por: Adegbola, Samuel O, et al.
Publicado: (2021)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Developing a core outcome set for fistulising perianal Crohn’s disease
por: Sahnan, Kapil, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2lm2bn5bf1m3hi28t294dbhfc4